

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-3. (canceled)

4. (currently amended) A method comprising transplantation of insulin producing cells in the form of isolating isolated islets to a patient suffering from insulin dependent diabetes mellitus (IDDM),

wherein said isolated islets are modified by irreversible adsorption with a clotting inhibiting agent comprising heparin or a fraction or derivative thereof,

wherein said islet cells are coated with heparin or a fraction or derivative thereof by preincubation of islets in a solution containing heparin or a fraction or derivative thereof,

wherein said anticoagulant clotting inhibiting agent acts to prevent inhibit clotting or reduce clotting.

5-7. (canceled)

8. (currently amended) The method according to any one of the claims 1-7 claim 4, wherein more than one clotting preventing inhibiting agent is used.

9. (currently amended) The method according to any one of the claims 1-7 claims 4, wherein the clotting preventing inhibiting agent is supplemented by an inhibitor of complement.

10. (canceled)

11. (currently amended) A method for increasing survival of islet cells according to claim 14, in connection with transplantation of insulin producing cells to patients with insulin dependent diabetes mellitus (IDDM), comprising prevention-inhibiting of clotting, monitored as reduced generation of thrombin-antithrombin complex (TAT complex).

12. (canceled)

13. (canceled)

14. (new) Isolated islets comprising insulin producing cells, wherein the islets are coated with a clotting inhibiting agent on the islet surface.

15. (new) Isolated islets of claim 14, wherein the clotting inhibiting agent is an anticoagulant.

16. (new) Isolated islets according to claim 15, wherein the anticoagulant is heparin or a fraction or derivative thereof.

17. (new) Isolated islets according to claim 16,  
wherein the isolated islet cells are coated with heparin or a  
fraction or derivative thereof by preincubation of islets in a  
solution containing heparin or a fraction or derivative  
thereof.

18. (new) Isolated islets of claim 14, wherein the  
clotting inhibiting agent is an inhibitor of platelet  
activation.

19. (new) Isolated islets according to claim 18,  
wherein the clotting inhibiting agent is a RGD containing  
peptide or a monoclonal antibody which inhibits the  
interaction of platelet integrins with their specific ligands.

20. (new) Isolated islets according to claim 19,  
wherein the clotting inhibiting agent is a monoclonal antibody  
or a peptide directed against the Fc receptor on platelets.

21. (new) Isolated islets according to claim 20,  
wherein said islets are coated with more than one clotting  
inhibiting agent.

22. (new) Isolated islets according to claim 20,  
wherein said islets are also coated with an inhibitor of  
complement.

23. (new) Isolated islets according to claim 21,  
wherein said islets are also coated with an inhibitor of  
complement.

24. (new) Isolated cells comprising islets of  
Langerhans, wherein the islets are coated with a heparin  
conjugate on the islet surface.

25. (new) Method of production of a composition for  
treatment of insulin dependent diabetes mellitus, IDDM,  
comprising coating isolated islets with a clotting inhibiting  
agent.